ARHGEF9 (Rho Guanine Nucleotide Exchange Factor 9), also known as collybistin, is a postsynaptic Rho guanine nucleotide exchange factor that plays a critical role in regulating synaptic plasticity, GABAergic signaling, and cytoskeletal dynamics. Mutations in ARHGEF9 are associated with epilepsy, intellectual disability, and autism spectrum disorders.
| ARHGEF9 Protein |
|---|
| Protein Name | Collybistin / ARHGEF9 |
| Gene | [ARHGEF9](/genes/arhgef9) |
| UniProt ID | [Q9UQB8](https://www.uniprot.org/uniprot/Q9UQB8) |
| PDB Structures | 2dl9, 2vmw |
| Molecular Weight | 56 kDa |
| Subcellular Localization | Postsynaptic density, plasma membrane, cytoskeleton |
| Protein Family | RhoGEF family, Dbl family |
¶ Domain Architecture
ARHGEF9 contains multiple functional domains:
- DH domain: Catalytic Dbl homology domain for Rho GTPase activation
- PH domain: Plextrin homology domain for membrane localization
- SH3 domain: Src homology 3 domain for protein-protein interactions
- PDZ-binding motif: C-terminal PDZ domain interaction motif
- Gephyrin Interaction: Recruits gephyrin to GABAergic postsynaptic sites
- GABA receptor Clustering: Critical for proper GABA-A receptor clustering
- Synaptic Plasticity: Regulates actin cytoskeleton at synapses
- Inhibitory Synapse Formation: Essential for formation and maintenance of inhibitory synapses
- Activates Cdc42 and Rac1 GTPases
- Links neuroligin-neurexin adhesion to intracellular signaling
- Modulates NMDA receptor function through actin remodeling
- ARHGEF9 mutations cause autosomal recessive epilepsy
- Loss of function leads to impaired GABAergic inhibition
- May contribute to seizure susceptibility in neurodegeneration
¶ Intellectual Disability and Autism
- De novo mutations identified in ID and ASD patients
- Altered synaptic inhibition contributes to neurodevelopmental phenotypes
- Potential link to synaptic dysfunction in neurodegeneration
- Altered Rho GTPase signaling in AD brain
- Dysregulated synaptic plasticity contributes to cognitive decline
- Potential therapeutic target for synapse stabilization
- Rho GTPase pathway alterations in PD models
- May affect dopaminergic neuron synaptic function
- Rho GTPase modulators in development
- GABAergic signaling enhancers
- Viral vector delivery of wild-type ARHGEF9
- CRISPR-based correction of pathogenic variants
- Knockout and transgenic mouse models
- In vitro neuronal differentiation models
- Kins et al., ARHGEF9 and gephyrin (2000)
- Papadopoulos et al., Collybistin function (2007)
- Harvey et al., ARHGEF9 mutations (2004)
- Betz et al., Gephyrin and synaptic inhibition (2001)